Fundamentals and Analysis While at an 8% weak sell today, the direction at Barchart is changing dramatically as it was a 56% sell last week. Not surprising as the exciting NRs were pending, daily trade volumes have been relatively low and the price point for Venowave had already been reached (imho) ....at least until there is more news on the purchase agreement.
The Morningstar Fair Value sp is in line with the current sp (that's great considering the obvious change in the algorithm for stocks which has dramatically altered the big day to day swings).
With fantastic results from Brazil testing, a pending FDA EUA (it seems highly unlikely this won't happen), a CE Mark ( that would only be enhanced with an FDA EUA) the minimum $10 million annual purchase agreement with DME Authority for Venowave and covid infection rates that are exploding again .....the patience of those holding long should finally be rewarded.
GLTE!!!